0001567619-22-012473.txt : 20220607
0001567619-22-012473.hdr.sgml : 20220607
20220607173657
ACCESSION NUMBER: 0001567619-22-012473
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220603
FILED AS OF DATE: 20220607
DATE AS OF CHANGE: 20220607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TAKANASHI KEN
CENTRAL INDEX KEY: 0001657768
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39041
FILM NUMBER: 221002097
MAIL ADDRESS:
STREET 1: C/O WAVE LIFE SCIENCES LTD.
STREET 2: 733 CONCORD AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Satsuma Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001692830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813039831
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 OYSTER POINT BOULEVARD
STREET 2: SUITE 221
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 64080
BUSINESS PHONE: 415-505-0809
MAIL ADDRESS:
STREET 1: 400 OYSTER POINT BOULEVARD
STREET 2: SUITE 221
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 64080
4
1
doc1.xml
FORM 4
X0306
4
2022-06-03
0
0001692830
Satsuma Pharmaceuticals, Inc.
STSA
0001657768
TAKANASHI KEN
C/O SATSUMA PHARMACEUTICALS, INC.
400 OYSTER POINT BOULEVARD, SUITE 221
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock, $0.0001 par value
1561719
I
See footnote
Stock Option (Right to Buy)
3.46
2022-06-03
4
A
0
30000
0.00
A
2032-06-02
Common Stock
30000
30000
D
Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting.
/s/ Thomas P. O'Neil as Attorney-in-Fact for Ken Takanashi
2022-06-07